Atypical presentation of Charcot-Marie-Tooth disease type 2Q by mutations on DHTKD1 and NTRK2 genes

Dulce M. Castro-Coyotl, Israel E. Crisanto-López*, Rosa M. Hernández-Camacho, and María P. Saldaña-Guerrero

1Centro de Rehabilitación e Inclusión Infantil Teleton; 2Departamento de Genética, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla; 3Departamento de Genética del Instituto Mexicano del Seguro Social. Puebla, Puebla, Mexico

Abstract

Background: Charcot-Marie-Tooth disease type 2Q (CMT2Q) is a rare disorder (< 1/1,000,000 individuals worldwide) linked to chromosome 10p14 in the DHTKD1 gene. This phenotype is characterized by an adolescent or adulthood-onset, slowly progressive distal muscle weakness and symmetrical atrophy associated with reduced or absent deep tendon reflexes. Currently, only two familiar cases from China have been reported: one familiar case of eight individuals affected by isolated DHTKD1 gene mutation and one familiar case of two individuals affected by DHTKD1 gene mutation and GJB1 gene mutation.

Case report: We present the case of a 10-year-old male patient with obesity, frequent falls, swollen legs and thighs, and pain in the lower and upper limbs. We performed the clinical evaluation and a clinical targeted exome test, which reported mutations on DHTKD1 and NTRK2 genes.

Conclusions: Due to scientific and technological advances, genetic dysfunctions that can cause different diseases have been identified with greater sensitivity. Globally, this is the eleventh case reported of DHTKD1 gene mutation linked to CMT2Q. Moreover, this is the first case related to NTRK2 gene mutation (linked to obesity, hyperphagia, and delayed development). The patient showed an atypical CMT2Q phenotype additional to obesity. Therefore, we propose to study metabolic disorders linked to hereditary peripheral neuropathies.

Keywords: Charcot-Marie-Tooth disease. Hereditary motor and sensory neuropathy. DHTKD1. NTRK2.
**Introduction**

Charcot-Marie-Tooth disease, also known as hereditary sensorimotor neuropathy, describes a large heterogeneous group of hereditary neuropathies1,2 representing the most common hereditary neuromuscular disease, with a prevalence of 1/2500 individuals worldwide3,4. Clinically, it affects the distal extremities, presenting progressive muscular and sensory defects, atrophy, and chronic weakness5. The inheritance pattern can be autosomal dominant (AD), autosomal recessive (AR), or X-linked. According to the motor conduction velocity (MCV) of the median nerve, these neuropathies are classified as demyelinating (MCV < 38 m/s), axonal (MCV > 38 m/s), and intermediate (MCV 30-40 m/s)5-8.

Dyck proposed to consider the neurophysiological and pathological findings to classify these conditions as type I (CMT1, hypertrophic or demyelinating) with AD or AR inheritance; type II (CMT2, neuronal or axonal) with AD or AR inheritance; type III (CMT3, with AR inheritance) reserved for Dejerine-Sottas disease or patients with severe forms of hypomyelinating CMT; X-linked complex forms, with optic atrophy, deafness, or retinal pigmentary degeneration9. Currently, etiopathological mechanisms have been established thanks to scientific and technological progress10, and the corresponding genetic alterations have been pinpointed, generating more specific genotypes of the disease11.

One of these genotypes is Charcot-Marie-Tooth disease type 2Q (CMT2Q) of AD inheritance. It is a rare phenotype (< 1/1,000,000 inhabitants worldwide), characterized by adolescence or adulthood onset. The patients present slowly and progressively muscle weakness and symmetric distal atrophy, predominantly in the lower extremities; other signs are pes cavus and mild to moderate deep sensory disturbances12. This disease is caused by a heterozygous mutation of the nuclear DHTKD1 (Dehydrogenase E1 and Transketolase Domain Containing 1) gene encoding the mitochondrial DHTKD1 protein13.

Recent studies have shown that the DHTKD1 gene produces the hE1 protein, which is part of the 2-ketoacidic acid complex, involved in the catabolism of lysine and tryptophan14-16, both directly related to the Krebs cycle and ATP production17,18. Mutations of this gene induced in experimental models produce blockage of metabolic pathways and 2-aminoacidic and 2-oxoacidic aciduria (AMOXAD)14,19.

In the literature, only eight patients (five males and three females) in a family from Shandong province, China, have been reported with the c.1455T>G (p.Tyr485) mutation in exon 8 of the DHTKD1 gene (in isolation)17. Furthermore, in 2019, Zhao et al. reported two more cases from another family in China with two mutations in CMT disease-related genes: the c.2369C>T mutation in the DHTKD1 gene and the mutation in c.258_530 of the AGT of the GJB1 (Gap Junction Beta 1) gene, which is a significant cause of X-linked CMT type 1 disease20,21.

For genetic diseases study protocols, specific techniques are used to determine alterations at the genomic level. One of them is the targeted exome test, which consists of the design of genetic panels based on the patient’s clinical history, in which a massive sequencing of more than 200,000 exons (99.68% of the coding human genome) is performed on a sample of the patient’s DNA. Subsequently, with a bioinformatics algorithm, the identified variants are prioritized based on their pathogenic potential. If they are not reported, in silico prediction of the variants is performed. If a diagnosis cannot be concluded, other genes can be included, or the entire exome can be analyzed.

The objective of this report was to present the eleventh case of a mutation in the DHTKD1 gene.
(associated with CMT2Q) and the first case related to a mutation in the NTRK2 gene (associated with obesity, hyperphagia, and developmental delay).

**Clinical case**

We present the case of a 10-year-and-11-month old male product of second pregnancy of non-consanguineous healthy parents (31-year-old mother, 33-year-old father) and a healthy 13-year-old sister, with no genetic history of any pathology similar to that of the patient. Adequate prenatal control started in the first trimester with a total of 10 consultations. With a normal pregnancy evolution, delivery was performed at 39 weeks via cesarean section due to placenta previa. The child cried and breathed at birth, and a weight of 3,100 grams and height of 51 cm were recorded; Apgar 10 at 5 minutes, without perinatal complications. Psychomotor development reported head support at 3 months, sitting at 6 months, standing at 10 months, walking at 16 months, beginning of monosyllables production at 22 months, complete sentences at 2.5 years, teething at 6 months, and sphincter control at 2 years.

At 10 years and 9 months, the patient began with muscle weakness and edema of the lower limbs, frequent falls, pain in upper and lower extremities, abdominal pain, diarrhea on average twice a week, sleep disturbances, and significant weight loss (approximately 20 kg in four months), for which the parents decided to seek medical attention.

The physical examination revealed a weight of 65 kg (Z score > 3, obesity), a height of 1.68 m (Z score > 3, very high), body mass index of 23 (Z score > 2, obesity). Also, normocephalus, cranial nerves examination without alterations, preserved cognitive functions, dislocated shoulders with full ranges of motion, slightly clawed hands, the strength of the four extremities was 5/5 in proximal and medial areas and 4/5 distally according to the Daniels scale, preserved sensitivity (proprioceptive and exteroceptive), positive muscle stretch reflex ++, gait without alterations, and normal psychomotor development.

The rehabilitation physician requested electromyography and specific laboratory studies; later, the patient was referred to the Genetics service for probable mitochondrial disease. Laboratory studies reported blood chemistry, aldolase, glutamic oxaloacetic transaminase, alanine aminotransferase, lactate dehydrogenase, and rheumatoid factor results within normal ranges. Biological markers results were as follows: creatine phosphokinase (CPK), 197 U/L (in normal parameter); CPK-MB, 25 ng/mL (high); lactate, 2.7 mmol/L (high). After observing elevated CPK-MB levels in a pediatric patient, the diagnosis was oriented towards a muscle-type alteration, such as dystrophy or myopathy, coupled with elevated lactate, which refers to an anaerobic pathway in adenosine triphosphate (ATP) synthesis. Radiology studies (chest X-ray, head magnetic resonance imaging, liver and bile duct ultrasound, and electrocardiogram) were reported without alterations. Electromyography and nerve conduction velocity concluded motor polyneuropathy with axonal degeneration. The myography study reported a mixed neuropathic and myopathic pattern.

Upon evaluation of the patient by a geneticist and according to the age group with symptoms of decreased muscle strength, significant weight loss, alteration of biological muscle markers, electromyography tests, and nerve conduction velocity, suspicion of mitochondrial neurogastrointestinal encephalomyopathy was concluded. We carried out an exome study for mitochondrial diseases; as a mitochondrial pathology was not detected, the search was extended to peripheral neuropathies. The directed exome genetic study reported two variants of uncertain clinical significance in a heterozygous state located in the **DHTKD1** gene [OMIM: 614984], associated with Charcot-Marie-Tooth disease type 2Q and NTRK2 [OMIM: 600456] associated with obesity, hyperphagia, and developmental delay. These variants were identified based on the GRCh38 reference genomic sequence and *in silico* prediction programs, using various databases to classify them according to their possible pathogenic potential.

**Discussion**

Only eight cases have been reported worldwide of CMT2Q disease attributed to the c.1455T>G (p.Tyr485) mutation of the **DHTKD1** gene [OMIM: 614984]. The present case is relevant due to the identification of two mutations. The first mutation, c.2090T>G, is a heterozygous transversion of a thymine residue by guanine at position 2090 of the coding region of the **DHTKD1** gene (exon 12 of 17), which generates a nonsynonymous change of a leucine residue by an arginine residue at position 697 of the encoded protein sequence. The second mutation, c.64C>A in the same gene, is another heterozygous transversion of a cytosine residue by an adenine at position 64 of the coding region of the **DHTKD1** gene (exon 1 of 17), which generates a nonsynonymous change of an arginine residue by
serine at position 22 of the encoded protein sequence. Based on the American College of Medical Genetics and Genomics guidelines, both mutations have been classified as of uncertain clinical significance. Although they rarely occur individually, \textit{in silico} analysis predicts them to be deleterious, and c.2090T>G is located in a functional domain of the encoded protein.

These results suggest the development of early-onset CMT2Q disease, which is consistent with motor axonal polyneuropathy in this patient.

Currently, the role of the \textit{DHTKD1} gene is still under study. It was demonstrated that it contributes to ATP production by degrading L-lysine, L-hydroxylysine, and L-tryptophan in the mitochondria within the Krebs cycle and reducing reactive oxygen species such as $\text{H}_2\text{O}_2$\textsuperscript{22-24}. In addition, it has been associated with conditions such as CMT2Q, AMOXAD, metabolic disorders, neurological abnormalities, and eosinophilic esophagitis\textsuperscript{25,26}.

The pathophysiology related to the mutation in \textit{DHTKD1} is not yet clear, but it is proposed that the levels of 2-ketoacidic acid (2-KAA) and 2-aminoacidic acid (2-AAA) increase. These high levels stimulate the biosynthesis and release of insulin, and subsequently the abnormal transcription of myelin protein zero (MPZ) in Schwann cells via early growth response 2 (Egr2), thus generating damage to the myelin structure and axonal degeneration. In other words, altered function of the \textit{DHTKD1} gene causes CMT2Q by dysregulation of MPZ mRNA expression\textsuperscript{18}.

Together, alterations in the \textit{DHTKD1} gene generate a decrease in ATP production, limiting the energy available for cellular functions. They also alter the biosynthesis and maintenance of mitochondria, unbalancing intracytoplasmic oxidizing agents and antioxidants, and increase the release of amino acid metabolites such as 2-KAA and 2-AAA, affecting MPZ mRNA expression.

Moreover, another c.2378C>G mutation was identified in the \textit{NTRK2} gene: a heterozygous transversion of a cytosine residue by guanine at position 2378 of the coding region of the \textit{NTRK2} gene (exon 19 of 19). This transversion generates a nonsynonymous change of a threonine residue to an arginine residue at position 793 of the encoded protein sequence. This variant was classified as being of uncertain clinical significance. Although it is localized within a functional domain of the encoded protein, it occurs at an extremely low frequency and is predicted to be deleterious \textit{in silico} (PP3).

These alterations may account for the atypical presentation of the patient. Pathogenic variants located in the \textit{NTRK2} gene are associated with obesity, hyperphagia, and developmental delay [OMIM: 613886], as well as with early-onset childhood epileptic encephalopathy [OMIM: 617830]\textsuperscript{27,29}.

This gene encodes a protein belonging to the neurotrophic tyrosine kinase receptor type II class IV family (TrkB), which is autophosphorylated in a ligand-dependent manner and phosphorylates proteins belonging to the mitogen-activated protein kinase (MAP kinase) pathway, leading to cell differentiation. TrkB protein is a receptor for neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). Thus, it is involved in the development and maturation of the central and peripheral nervous system by regulating neuronal survival, proliferation, migration, differentiation, synapse formation, and plasticity (by similarity)\textsuperscript{27,29}.

In conclusion, the mutation variants presented in this case have not been reported as potentially pathogenic in any public database. However, the patient’s clinical presentation is consistent with the alterations of both genetic mutations reported in different studies. The present report contributes to the scientific evidence of the relationship between metabolic disorders and mitochondrial dysfunction as causes of peripheral neuropathies.

\textbf{Ethical disclosures}

\textbf{Protection of human and animal subjects.} The authors declare that no experiments were performed on humans or animals for this study.

\textbf{Confidentiality of data.} The authors declare that they have followed the protocols of their work center on the publication of patient data.

\textbf{Right to privacy and informed consent.} The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author has this document.

\textbf{Conflicts of interest} The authors declare no conflicts of interest since the professional judgment was focused only on the patient’s well-being.

\textbf{Conflicts of interest} The authors declare no conflict of interest.

\textbf{Funding} None.
References


